Brief: Mabpharm Says New Drug Application For CMAB008 Submitted In China
30/12/2019 12:28
Dec 30 (Reuters) - Mabpharm Ltd 2181.HK :
* NEW DRUG APPLICATION FOR CMAB008 SUBMITTED TO NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION OF CHINA
Source text for Eikon: ID:nHKS5lgnDK
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008